Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Novo Nordisk said on Tuesday it was working with telehealth firms Hims & Hers , Ro and LifeMD to sell Wegovy, as it looks to ...

Novo Nordisk A/S said it would sell its popular weight-loss drug Wegovy for a steeply reduced price on several telehealth ...

Novo Nordisk saw a significant decline as it lost over 55% from its highs in June 2024. Check out the reasons for the decline ...

Data across obesity, cardiovascular disease, MASH, type 2 diabetes, as well as advances in obesity-related care to be presented at ECO 2025 - covering burden, and the value of treatment and prevention ...

Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with ...

Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...